|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
EP1687308B1
(en)
*
|
2003-11-17 |
2019-06-12 |
Merck & Cie |
Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms
|
|
CN103435581B
(zh)
*
|
2004-03-16 |
2015-08-19 |
贝林格尔.英格海姆国际有限公司 |
吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
|
|
US20070249827A1
(en)
*
|
2004-06-02 |
2007-10-25 |
Sandoz Ag |
Meropenem Intermediatein in Crystalling Form
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
ES2314743T3
(es)
*
|
2004-12-16 |
2009-03-16 |
Boehringer Ingelheim International Gmbh |
Derivados de benceno sustituidos con glucopiranosilo, medicamentos que contienen a este tipo de compuestos, su uso y procedimiento para su fabricacion.
|
|
EP1856082B1
(en)
*
|
2005-02-23 |
2009-10-14 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
|
|
CA2605245A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
|
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
|
US7723309B2
(en)
*
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
|
US7772191B2
(en)
*
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
|
EP1910393A2
(en)
*
|
2005-07-05 |
2008-04-16 |
Hetero Drugs Limited |
A novel process for the preparation of didanosine using novel intermediates
|
|
DE602006014411D1
(de)
*
|
2005-07-27 |
2010-07-01 |
Boehringer Ingelheim Pharma |
Glucopyranosyl-substituierte ((hetero)cycloalyklethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters (sglt)
|
|
EP1924571B1
(en)
*
|
2005-08-30 |
2010-10-13 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
DE602006018961D1
(de)
|
2005-09-08 |
2011-01-27 |
Boehringer Ingelheim Pharma |
KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZOL, ZUBEREITUNGSVERFAHREN DAFÜR UND DESSEN VERWENDUNG ZUR ARZNEIMITTELHERSTELLUNG
|
|
AR056195A1
(es)
*
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
|
NZ566073A
(en)
*
|
2005-09-21 |
2011-08-26 |
4Sc Ag |
Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
|
|
CN101389617A
(zh)
*
|
2005-10-31 |
2009-03-18 |
詹森药业有限公司 |
制备哌嗪基和二氮杂环庚烷基苯甲酰胺衍生物的新方法
|
|
EA200801773A1
(ru)
*
|
2006-02-15 |
2009-02-27 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Глюкопиранозилзамещенные производные бензонитрила, фармацевтические композиции, содержащие такие соединения, их применение и способ их получения
|
|
PE20080697A1
(es)
*
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
SG174054A1
(en)
|
2006-05-04 |
2011-09-29 |
Boehringer Ingelheim Int |
Polymorphs
|
|
AU2007260356B2
(en)
*
|
2006-06-16 |
2013-01-24 |
H. Lundbeck A/S |
Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
|
|
US8039441B2
(en)
*
|
2006-08-15 |
2011-10-18 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
|
|
EP2074130A1
(en)
*
|
2006-09-21 |
2009-07-01 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
US8283326B2
(en)
*
|
2006-10-27 |
2012-10-09 |
Boehringer Ingelheim International Gmbh |
Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
|
KR20150028857A
(ko)
*
|
2006-10-27 |
2015-03-16 |
시그날 파마소티칼 엘엘씨 |
4-[9-(테트라하이드로-퓨란-3-일)-8-(2,4,6-트리플루오로-페닐아미노)-9ｈ-퓨린-2-일아미노]-사이클로헥산-1-올을포함하는 고체 형태들, 이들의 조성물들 및 이들의 용도
|
|
TW200829258A
(en)
|
2006-11-06 |
2008-07-16 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
CN101568537A
(zh)
|
2006-12-21 |
2009-10-28 |
安斯泰来制药有限公司 |
C-糖苷衍生物的制造方法及其合成中间体
|
|
WO2008101939A1
(en)
|
2007-02-21 |
2008-08-28 |
Boehringer Ingelheim International Gmbh |
Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
PE20090938A1
(es)
*
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
EP3318562A3
(en)
|
2007-08-23 |
2018-09-12 |
Theracos Sub, LLC |
Benzylbenzene derivatives and methods of use
|
|
US8648085B2
(en)
*
|
2007-11-30 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
|
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
|
EP2085397A1
(en)
*
|
2008-01-21 |
2009-08-05 |
Esteve Quimica, S.A. |
Crystalline form of abacavir
|
|
CN101969944B
(zh)
*
|
2008-01-31 |
2013-04-10 |
安斯泰来制药有限公司 |
脂肪性肝病的治疗用医药组合物
|
|
US7935817B2
(en)
*
|
2008-03-31 |
2011-05-03 |
Apotex Pharmachem Inc. |
Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
|
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
|
AR071318A1
(es)
*
|
2008-04-15 |
2010-06-09 |
Basilea Pharmaceutica Ag |
Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
|
|
US8097719B2
(en)
*
|
2008-07-15 |
2012-01-17 |
Genesen Labs |
Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
|
|
US9061060B2
(en)
|
2008-07-15 |
2015-06-23 |
Theracos Inc. |
Deuterated benzylbenzene derivatives and methods of use
|
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
HRP20161648T1
(hr)
|
2008-08-22 |
2017-02-10 |
Theracos Sub, Llc |
Postupak za pripravu sglt2 inhibitora
|
|
ATE540040T1
(de)
|
2008-08-28 |
2012-01-15 |
Pfizer |
Dioxabicycloä3.2.1üoctan-2,3,4-triolderivate
|
|
JP5453431B2
(ja)
|
2008-09-08 |
2014-03-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
AU2014200258B2
(en)
*
|
2009-02-13 |
2016-05-12 |
Boehringer Ingelheim International Gmbh |
SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
|
AU2016213789B2
(en)
*
|
2009-02-13 |
2018-01-18 |
Boehringer Ingelheim International Gmbh |
SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
|
GEP20146120B
(en)
|
2009-02-13 |
2014-07-25 |
Boehringer Ingelheim Int |
Sglt-2 inhibitor for treating type i diabetes mellitus, type ii diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
|
SG173619A1
(en)
|
2009-02-13 |
2011-09-29 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
|
|
LT2395968T
(lt)
*
|
2009-02-13 |
2024-02-26 |
Boehringer Ingelheim International Gmbh |
Farmacinė kompozicija, apimanti gliukopiranozildifenilmetano darinius, jų farmacines dozavimo formas, jų gamybos būdą ir naudojimą patobulintai glikeminei kontrolei paciento organizme
|
|
UY32427A
(es)
*
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
PT2414363E
(pt)
*
|
2009-03-31 |
2014-02-26 |
Boehringer Ingelheim Int |
Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
|
|
TW201118099A
(en)
*
|
2009-08-12 |
2011-06-01 |
Boehringer Ingelheim Int |
New compounds for the treatment of CNS disorders
|
|
CN102574829B
(zh)
|
2009-09-30 |
2015-07-01 |
贝林格尔.英格海姆国际有限公司 |
吡喃葡萄糖基取代的苄基-苯衍生物的制备方法
|
|
MX2012002942A
(es)
*
|
2009-09-30 |
2012-04-11 |
Boehringer Ingelheim Int |
Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno.
|
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
|
US8163704B2
(en)
|
2009-10-20 |
2012-04-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
|
ME02016B
(me)
|
2009-11-02 |
2015-05-20 |
Pfizer |
Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
|
|
BR112012012641A2
(pt)
|
2009-11-27 |
2020-08-11 |
Boehringer Ingelheim International Gmbh |
TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
|
|
ES2742195T3
(es)
|
2010-03-12 |
2020-02-13 |
Omeros Corp |
Inhibidores de PDE10 y composiciones y métodos relacionados
|
|
JP2013523681A
(ja)
*
|
2010-03-30 |
2013-06-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
|
|
KR101927068B1
(ko)
|
2010-05-05 |
2018-12-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
|
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
|
NZ603725A
(en)
|
2010-08-12 |
2015-04-24 |
Boehringer Ingelheim Int |
6-cycloalkyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
|
|
SG188361A1
(en)
*
|
2010-09-01 |
2013-04-30 |
Arena Pharm Inc |
Non-hygroscopic salts of 5-ht2c agonists
|
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
|
WO2012059416A1
(en)
|
2010-11-02 |
2012-05-10 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations for the treatment of metabolic disorders
|
|
US20120283169A1
(en)
*
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
|
EA201301354A1
(ru)
|
2011-06-03 |
2014-05-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
|
|
US20130035298A1
(en)
*
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
JP2014530805A
(ja)
*
|
2011-09-30 |
2014-11-20 |
スンシネ ルアケ プハルマ カンパニー リミテッド |
アジルサルタンの結晶形並びにその製造及び使用
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
|
CA2872932A1
(en)
|
2012-05-09 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations for the treatment of metabolic disorders
|
|
EP4151218A1
(en)
|
2012-05-14 |
2023-03-22 |
Boehringer Ingelheim International GmbH |
Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
|
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
|
|
EP2981269B9
(en)
|
2013-04-04 |
2023-12-06 |
Boehringer Ingelheim Vetmedica GmbH |
Treatment of metabolic disorders in equine animals
|
|
HK1213818A1
(zh)
*
|
2013-04-05 |
2016-07-15 |
勃林格殷格翰国际有限公司 |
依帕列净的治疗用途
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CA2812016A1
(en)
*
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US20160000816A1
(en)
*
|
2013-04-05 |
2016-01-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
HUE041709T2
(hu)
*
|
2013-04-05 |
2019-05-28 |
Boehringer Ingelheim Int |
Az empagliflozin terápiás alkalmazásai
|
|
PT2986304T
(pt)
|
2013-04-18 |
2022-02-25 |
Boehringer Ingelheim Int |
Composição farmacêutica, métodos para o tratamento e suas utilizações
|
|
WO2015051484A1
(en)
|
2013-10-12 |
2015-04-16 |
Theracos, Inc. |
Preparation of hydroxy-benzylbenzene derivatives
|
|
PL3082829T3
(pl)
|
2013-12-17 |
2021-09-06 |
Boehringer Ingelheim Vetmedica Gmbh |
Inhibitory sglt2 do leczenia zaburzeń metabolicznych u zwierząt kotowatych
|
|
US9902751B2
(en)
|
2013-12-30 |
2018-02-27 |
Mylan Laboratories Limited |
Process for the preparation of empagliflozin
|
|
PL3096765T3
(pl)
*
|
2014-01-23 |
2019-05-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Leczenie zaburzeń metabolicznych u zwierząt psowatych
|
|
KR102662473B1
(ko)
|
2014-04-01 |
2024-05-03 |
베링거잉겔하임베트메디카게엠베하 |
말과 동물에서 대사 장애의 치료
|
|
NZ716462A
(en)
*
|
2014-04-28 |
2017-11-24 |
Omeros Corp |
Optically active pde10 inhibitor
|
|
NZ716494A
(en)
|
2014-04-28 |
2017-07-28 |
Omeros Corp |
Processes and intermediates for the preparation of a pde10 inhibitor
|
|
CN105384730A
(zh)
*
|
2014-09-03 |
2016-03-09 |
杭州普晒医药科技有限公司 |
依帕列净的晶型及其制备方法、药物组合物和用途
|
|
CN105481843A
(zh)
*
|
2014-09-19 |
2016-04-13 |
重庆医药工业研究院有限责任公司 |
一种恩格列净无定型物及其制备方法
|
|
AU2015320975B2
(en)
|
2014-09-25 |
2020-10-08 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
|
|
EP3201191A1
(en)
|
2014-10-01 |
2017-08-09 |
Mylan Laboratories Ltd. |
Complex of amorphous empagliflozin and a cyclodextrin
|
|
CZ2015110A3
(cs)
|
2015-02-18 |
2016-08-31 |
Zentiva, K.S. |
Pevné formy empagliflozinu
|
|
WO2016144862A1
(en)
|
2015-03-09 |
2016-09-15 |
Intekrin Therapeutics, Inc. |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
|
CZ2015279A3
(cs)
|
2015-04-24 |
2016-11-02 |
Zentiva, K.S. |
Pevné formy amorfního empagliflozinu
|
|
AU2016250843A1
(en)
|
2015-04-24 |
2017-10-12 |
Omeros Corporation |
PDE10 inhibitors and related compositions and methods
|
|
CN104788438B
(zh)
*
|
2015-05-04 |
2018-02-02 |
南京华威医药科技集团有限公司 |
恩格列净b晶型及其制备
|
|
CN106317035A
(zh)
*
|
2015-06-23 |
2017-01-11 |
中美华世通生物医药科技（武汉）有限公司 |
恩格列净单晶及其制备方法和用途
|
|
NZ739429A
(en)
|
2015-08-27 |
2023-03-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Liquid pharmaceutical compositions comprising sglt-2 inhibitors
|
|
EP3362055B1
(en)
|
2015-10-15 |
2023-01-18 |
Boehringer Ingelheim International GmbH |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
|
WO2017079678A1
(en)
|
2015-11-04 |
2017-05-11 |
Omeros Corporation |
Solid state forms of a pde10 inhibitor
|
|
WO2017141202A1
(en)
*
|
2016-02-17 |
2017-08-24 |
Lupin Limited |
Complex of sglt2 inhibitor and process for preparation thereof
|
|
KR20240095321A
(ko)
*
|
2016-03-16 |
2024-06-25 |
베링거 인겔하임 인터내셔날 게엠베하 |
엠파글리플로진을 포함하는 약제학적 조성물 및 이의 용도
|
|
WO2017203457A1
(en)
*
|
2016-05-26 |
2017-11-30 |
Dr. Reddy's Laboratories Limited |
Solid state forms of empagliflozin
|
|
WO2017211979A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
|
US20190309004A1
(en)
|
2016-10-13 |
2019-10-10 |
Boehringer Ingelheim International Gmbh |
Process for preparing glucopyranosyl-substituted benzyl-benzene derivatives
|
|
EA201990951A1
(ru)
|
2016-10-19 |
2019-11-29 |
|
Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
|
|
AU2017357589B2
(en)
|
2016-11-10 |
2023-05-11 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
WO2018163194A1
(en)
*
|
2017-03-10 |
2018-09-13 |
Msn Laboratories Private Limited, R&D Center |
A process for the preparation of d-glucitol, 1,5-anhydro-1-c-[4-chloro-3-[[4- [[(3s)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, ( 1 s)
|
|
KR20200036808A
(ko)
|
2017-04-03 |
2020-04-07 |
코히러스 바이오사이언시스, 인크. |
진행성 핵상 마비 치료를 위한 PPARγ 작용제
|
|
EP3781166A1
(en)
|
2018-04-17 |
2021-02-24 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CZ2018188A3
(cs)
|
2018-04-18 |
2019-10-30 |
Zentiva, K.S. |
Částice s obsahem amorfního empagliflozinu, způsob jejich přípravy a farmaceutický přípravek
|
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
|
JP2021532191A
(ja)
|
2018-07-25 |
2021-11-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アルポート症候群の治療に使用するためのエンパグリフロジン
|
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
|
WO2020058095A1
(en)
|
2018-09-19 |
2020-03-26 |
Galenicum Health S.L.U. |
Pharmaceutical compositions of empagliflozin
|
|
WO2020087031A1
(en)
|
2018-10-26 |
2020-04-30 |
The Research Foundation For The State University Of New York |
Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
|
|
US12213970B2
(en)
|
2018-10-29 |
2025-02-04 |
Boehringer Ingelheim International Gmbh |
Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
|
|
PH12021550901A1
(en)
|
2018-10-29 |
2022-03-21 |
Boehringer Ingelheim Int |
Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
|
|
US11759474B2
(en)
|
2019-11-28 |
2023-09-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of SGLT-2 inhibitors in the drying-off of non-human mammals
|
|
WO2021123165A1
(en)
|
2019-12-19 |
2021-06-24 |
Krka, D.D., Novo Mesto |
Dosage form comprising amorphous solid solution of empagliflozin with polymer
|
|
KR102111248B1
(ko)
|
2019-12-30 |
2020-05-14 |
유니셀랩 주식회사 |
새로운 엠파글리플로진의 공결정
|
|
CN118615450A
(zh)
|
2020-02-17 |
2024-09-10 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
|
|
KR20220151634A
(ko)
|
2020-03-06 |
2022-11-15 |
버텍스 파마슈티칼스 인코포레이티드 |
Apol-1 의존성 국소 분절성 사구체경화증을 치료하는 방법
|
|
CN111303230B
(zh)
*
|
2020-03-09 |
2021-07-13 |
中国食品药品检定研究院 |
一种黄体酮共晶物及其制备方法和用途
|
|
KR102207319B1
(ko)
|
2020-03-23 |
2021-01-25 |
유니셀랩 주식회사 |
새로운 엠파글리플로진의 공결정
|
|
KR102150825B1
(ko)
|
2020-04-06 |
2020-09-03 |
유니셀랩 주식회사 |
새로운 sglt-2 억제제의 신규한 공결정
|
|
WO2021204756A1
(en)
|
2020-04-07 |
2021-10-14 |
Boehringer Ingelheim International Gmbh |
Methods for the treatment of headache disorders
|
|
JP2023523596A
(ja)
|
2020-04-22 |
2023-06-06 |
バイエル アクチェンゲゼルシャフト |
心血管疾患および／または腎疾患を治療および／または予防するためのフィネレノンとｓｇｌｔ２阻害剤の組み合わせ
|
|
WO2021250565A1
(en)
*
|
2020-06-10 |
2021-12-16 |
Hikal Limited |
An improved process for preparation of empagliflozin and its crystalline polymorph
|
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
|
KR102218323B1
(ko)
|
2020-09-09 |
2021-02-22 |
유니셀랩 주식회사 |
효율적이고 상전이가 되지 않는 엠파글리플로진 무정형의 제조방법
|
|
KR20220080880A
(ko)
|
2020-12-08 |
2022-06-15 |
주식회사 종근당 |
엠파글리플로진 공결정을 함유하는 약제학적 조성물
|
|
WO2023006745A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
|
CA3224673A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
|
|
WO2023006718A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
|
|
JP2025501336A
(ja)
|
2021-12-30 |
2025-01-17 |
ニューアムステルダム ファーマ ベー．フェー． |
オビセトラピブとｓｇｌｔ２阻害剤との組み合わせ
|
|
AU2023277704A1
(en)
|
2022-05-25 |
2024-12-05 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
|
EP4299055A1
(en)
|
2022-06-29 |
2024-01-03 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Oral dosage formulations comprising empagliflozin
|
|
EP4342459A1
(en)
|
2022-09-20 |
2024-03-27 |
Galenicum Health S.L.U. |
Pharmaceutical compositions of empagliflozin
|
|
EP4378455A1
(en)
|
2022-11-29 |
2024-06-05 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A pharmaceutical formulation comprising empagliflozin
|
|
EP4420658A1
(en)
|
2023-02-24 |
2024-08-28 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A film coated tablet comprising empagliflozin
|
|
AU2024233233A1
(en)
|
2023-03-06 |
2025-09-11 |
Boehringer Ingelheim Vetmedica Gmbh |
Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
|
|
EP4442252A1
(en)
|
2023-04-04 |
2024-10-09 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A tablet formulation of a solid dispersion comprising empagliflozin
|
|
EP4442253A1
(en)
|
2023-04-04 |
2024-10-09 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A film coated tablet comprising empagliflozin and surfactant
|
|
EP4442254A1
(en)
|
2023-04-04 |
2024-10-09 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Film coated tablets comprising empagliflozin
|
|
TW202446389A
(zh)
|
2023-04-24 |
2024-12-01 |
荷蘭商新阿姆斯特丹製藥公司 |
非晶形奧比特拉(obicetrapib)與sglt2抑制劑之組合
|
|
WO2024240632A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
|
|
TW202508455A
(zh)
|
2023-05-24 |
2025-03-01 |
德商百靈佳殷格翰維美迪加股份有限公司 |
包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
|
|
KR20250007816A
(ko)
|
2023-07-06 |
2025-01-14 |
주식회사 경보제약 |
엠파글리플로진 ２ｌ프롤린의 신규 결정형 및 이의 제조방법
|
|
KR20250038170A
(ko)
|
2023-09-11 |
2025-03-19 |
동광제약 주식회사 |
엠파글리플로진의 무정형 안정화 방법
|
|
WO2025191117A1
(en)
|
2024-03-15 |
2025-09-18 |
Inventiva |
Prevention of blood disorders in patient treated with a ppar agonist
|
|
WO2025224069A1
(en)
|
2024-04-23 |
2025-10-30 |
Bayer Aktiengesellschaft |
Co-crystals of finerenone, pecavaptan, and sglt2 inhibitors
|
|
CN119735586A
(zh)
*
|
2025-02-25 |
2025-04-01 |
济南大学 |
一种恩格列净晶型iii及其制备方法
|